<div id="readability-page-1"><p>Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $36.13 and last traded at $35.83, with a volume of 3355702 shares traded. The stock had previously closed at $33.05.</p><div><p><span></span><span>Get <strong>Olema Pharmaceuticals</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><p>A number of equities research analysts have recently commented on OLMA shares. UBS Group  reaffirmed a &#34;buy&#34; rating on shares of Olema Pharmaceuticals in a research note on Monday, October 20th. The Goldman Sachs Group boosted their target price on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, December 11th. HC Wainwright increased their price target on Olema Pharmaceuticals from $36.00 to $45.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, December 11th. Guggenheim initiated coverage on Olema Pharmaceuticals in a research report on Wednesday, October 8th. They issued a &#34;buy&#34; rating and a $20.00 price objective for the company. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $40.50.</p><p><b>Read Our Latest Report on OLMA</b></p><h2>Olema Pharmaceuticals Stock Performance</h2><p>The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The company's fifty day moving average price is $16.23 and its 200 day moving average price is $9.47. The company has a market cap of $2.46 billion, a PE ratio of -19.16 and a beta of 1.87. </p><p>Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.05).  On average, equities research analysts predict that  Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year. </p><h2>Insider Activity</h2><p>In related news, Director Cyrus Harmon sold 10,000 shares of the stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $8.33, for a total transaction of $83,300.00. Following the completion of the sale, the director directly owned 744,140 shares of the company's stock, valued at approximately $6,198,686.20. This trade represents a 1.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 16.36% of the stock is currently owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors have recently bought and sold shares of OLMA. Ameritas Investment Partners Inc. increased its position in shares of  Olema Pharmaceuticals by 55.4% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company's stock valued at $26,000 after purchasing an additional 2,168 shares during the last quarter.  Farther Finance Advisors LLC increased its holdings in  Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company's stock worth $29,000 after buying an additional 5,866 shares during the last quarter.  FNY Investment Advisers LLC increased its holdings in  Olema Pharmaceuticals by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company's stock worth $42,000 after buying an additional 5,000 shares during the last quarter.  Quarry LP bought a new stake in  Olema Pharmaceuticals in the first quarter worth about $45,000.  Finally, Alpine Global Management LLC purchased a new position in  Olema Pharmaceuticals in the first quarter valued at about $52,000. Institutional investors own  91.78% of the company's stock. </p><h2>Olema Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Olema Pharmaceuticals</li><li>How to Invest in Small Cap Stocks </li><li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li><li>3 Warren Buffett Stocks to Buy Now</li><li>Dell and HP Are Raising Prices—And Investors Should Take Note</li><li>What Is WallStreetBets and What Stocks Are They Targeting?</li><li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Olema Pharmaceuticals Right Now?</h2><p>Before you consider Olema Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.</p><p>While Olema Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OLMA

<p>Olema Pharmaceuticals (NASDAQ:OLMA) reached a new 52-week high, trading at $36.13 with a volume of 3,355,702 shares. Analysts have given mixed ratings, with a consensus of 'Moderate Buy' and a price target of $40.50. The company reported a Q3 loss of $0.49 per share. Insider activity includes a sale by Director Cyrus Harmon. Institutional investors own 91.78% of the stock. Olema focuses on therapies for women's cancers, with its lead product OP-1250 in Phase 3 trials.</p>

Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 12-Month High - Time to Buy?